Abstract
The article provides information on the prevalence of metabolic syndrome in patients with psoriasis. The criteria for the diagnosis of metabolic syndrome are presented. The General mechanisms of inflam - mation development in psoriasis and diseases forming the metabolic syndrome are described. Systemic subclinical inflammatory process developing in psoriasis and metabolic syndrome is considered as the main pathogenetic mechanism of their mutual negative influence. The difficulties of treatment of patients with psoriasis with metabolic syndrome are largely associated with the choice of a safe and effective method of treatment. The description of the drug apremilast (OTEZLA®) is a selective inhibitor of the enzyme phosphodiesterase 4, which may be the best drug in the therapy of patients with psoriasis and metabolic syndrome.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
